• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性局灶节段性肾小球硬化症(FSGS)的肾脏预后:应用预测模型。

Kidney Outcome in Primary Focal Segmental Glomerulosclerosis (FSGS) by Using a Predictive Model.

机构信息

Department of Medicine, Nephrology Section, Iran University of Medical Sciences (IUMS), Hasheminejad Kidney Center (HKC), Tehran, Iran.

出版信息

Iran J Kidney Dis. 2021 Dec;15(6):408-418.

PMID:34930852
Abstract

INTRODUCTION

Focal segmental glomerulosclerosis (FSGS) is one of the important causes of end stage kidney disease (ESKD). We evaluated the progression risk factors of primary FSGS to chronic kidney disease (CKD) or ESKD with a predictive model including clinical and histological predictors.

METHODS

201 patients with primary FSGS (59% male, mean age: 38 ± 15 years), were studied. Time-dependent Cox model and C statistics were used for the predictive model. Interaction and correlation between independent variables were estimated.

RESULTS

During 55 ± 27 months of follow-up, 82 patients (41%) developed CKD (46) or ESKD (36) patients. In adjusted model, 1 unit of higher serum creatinine (SCr) at baseline (HR = 1.39, 95% CI: 1.15 to 1.70) and 1% increase in glomeruli with segmental glomerulosclerosis (SGS) (HR = 1.03, 95% CI: 1.02 to 1.04) or interstitial fibrosis/tubular atrophy (IF/TA) (HR = 1.03, 95% CI: 1.01 to 1.05) increased the risk of CKD/ESKD. In adjusted model, higher baseline proteinuria and collapsing variant were not associated with risk of CKD/ESKD. By adding SGS and IF/TA scores to baseline SCr in the model, discrimination by C statistics was 0.83 (95% CI: 0.77 to 0.90). Median renal survival was 3.1 years (95% CI: 2.2 to 4.1 years) in patients with highest risk score (baseline eGFR < 25 mL/min/1.73m2 + IF/TA/SGS > 50%), and 8.1 years (95% CI: 7.7 to 8.6 years).in those with lowest score (baseline eGFR > 75 mL/ min/1.73m2 + IF/TA/SGS < 5%).

CONCLUSION

In primary FSGS, higher baseline SCr, increased SGS and IF/TA, but not baseline proteinuria and collapsing pathology, were the predictors for CKD/ESKD. These findings indicated the importance of timely detection and referral in prognosis of primary FSGS. DOI: 10.52547/ijkd.6442.

摘要

简介

局灶节段性肾小球硬化症(FSGS)是终末期肾病(ESKD)的重要病因之一。我们评估了包括临床和组织学预测因子在内的预测模型中原发性 FSGS 向慢性肾脏病(CKD)或 ESKD 进展的风险因素。

方法

研究了 201 名原发性 FSGS 患者(59%为男性,平均年龄:38±15 岁)。使用时间依赖性 Cox 模型和 C 统计量进行预测模型。估计了独立变量之间的相互作用和相关性。

结果

在 55±27 个月的随访期间,82 名患者(41%)出现 CKD(46 名)或 ESKD(36 名)。在调整后的模型中,基线时血清肌酐(SCr)升高 1 单位(HR=1.39,95%CI:1.15 至 1.70)和肾小球节段性肾小球硬化(SGS)增加 1%(HR=1.03,95%CI:1.02 至 1.04)或间质纤维化/肾小管萎缩(IF/TA)(HR=1.03,95%CI:1.01 至 1.05)都会增加 CKD/ESKD 的风险。在调整后的模型中,较高的基线蛋白尿和塌陷变体与 CKD/ESKD 风险无关。通过将 SGS 和 IF/TA 评分添加到基线 SCr 中,C 统计量的区分度为 0.83(95%CI:0.77 至 0.90)。在风险评分最高的患者(基线 eGFR<25mL/min/1.73m2+IF/TA/SGS>50%)中,中位肾脏生存率为 3.1 年(95%CI:2.2 至 4.1 年),而在风险评分最低的患者(基线 eGFR>75mL/min/1.73m2+IF/TA/SGS<5%)中为 8.1 年(95%CI:7.7 至 8.6 年)。

结论

在原发性 FSGS 中,较高的基线 SCr、增加的 SGS 和 IF/TA,但不是基线蛋白尿和塌陷病理学,是 CKD/ESKD 的预测因子。这些发现表明及时发现和转介对原发性 FSGS 预后的重要性。DOI:10.52547/ijkd.6442.

相似文献

1
Kidney Outcome in Primary Focal Segmental Glomerulosclerosis (FSGS) by Using a Predictive Model.原发性局灶节段性肾小球硬化症(FSGS)的肾脏预后:应用预测模型。
Iran J Kidney Dis. 2021 Dec;15(6):408-418.
2
Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease.尿纤溶酶原作为人类肾小球疾病疾病进展的标志物。
Am J Kidney Dis. 2024 Aug;84(2):205-214.e1. doi: 10.1053/j.ajkd.2024.01.520. Epub 2024 Mar 5.
3
Oral adsorbents for preventing or delaying the progression of chronic kidney disease.用于预防或延缓慢性肾脏病进展的口服吸附剂。
Cochrane Database Syst Rev. 2014 Oct 15;2014(10):CD007861. doi: 10.1002/14651858.CD007861.pub2.
4
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.司帕生坦与厄贝沙坦治疗局灶节段性肾小球硬化症的比较
N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.
5
Population risk predictors of major adverse kidney events attributed to focal segmental glomerulosclerosis from the CURE-CKD registry.来自CURE-CKD注册研究的局灶节段性肾小球硬化所致主要不良肾脏事件的人群风险预测因素
BMC Nephrol. 2025 Jul 19;26(1):403. doi: 10.1186/s12882-025-04334-6.
6
Interventions for focal segmental glomerulosclerosis in adults.成人局灶节段性肾小球硬化的治疗。
Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.
7
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
8
Histologic predictors of kidney outcomes in LN: re-evaluating the role of segmental glomerulosclerosis in the chronicity index.狼疮性肾炎肾脏预后的组织学预测指标:重新评估节段性肾小球硬化在慢性指数中的作用。
Rheumatology (Oxford). 2025 Aug 1;64(8):4787-4795. doi: 10.1093/rheumatology/keaf194.
9
Hospitalizations among adults with chronic kidney disease in the United States: A cohort study.美国慢性肾脏病成人患者的住院情况:一项队列研究。
PLoS Med. 2020 Dec 11;17(12):e1003470. doi: 10.1371/journal.pmed.1003470. eCollection 2020 Dec.
10
Protein Carbamylation and the Risk of ESKD in Patients with CKD.蛋白质碳氨化与慢性肾脏病患者发生终末期肾病的风险。
J Am Soc Nephrol. 2023 May 1;34(5):876-885. doi: 10.1681/ASN.0000000000000078. Epub 2023 Jan 21.

引用本文的文献

1
Population Risk Predictors of Major Adverse Kidney Events in Patients with Focal Segmental Glomerulosclerosis from the CURE-CKD Registry.来自CURE-CKD注册研究的局灶节段性肾小球硬化患者主要不良肾脏事件的人群风险预测因素
Res Sq. 2025 May 6:rs.3.rs-5844460. doi: 10.21203/rs.3.rs-5844460/v1.
2
Clinical course and outcome of adult patients with primary focal segmental glomerulosclerosis with kidney function loss on presentation.初诊时伴有肾功能丧失的成人原发性局灶节段性肾小球硬化症患者的临床病程及预后
World J Nephrol. 2024 Dec 25;13(4):98932. doi: 10.5527/wjn.v13.i4.98932.
3
A new index for the outcome of focal segmental glomerulosclerosis.
一种新的局灶节段性肾小球硬化结局指标。
Sci Rep. 2024 Apr 9;14(1):8278. doi: 10.1038/s41598-024-59007-5.
4
Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis.开发并验证预测局灶节段性肾小球硬化症肾衰竭的风险评分。
Kidney Dis (Basel). 2023 Mar 28;9(4):285-297. doi: 10.1159/000529773. eCollection 2023 Aug.
5
Clinical Outcomes in Patients With Biopsy Proven Anticoagulant-Related Nephropathy.经活检证实的抗凝相关肾病患者的临床结局
Kidney Int Rep. 2023 Apr 24;8(7):1445-1448. doi: 10.1016/j.ekir.2023.04.014. eCollection 2023 Jul.